Merck KGaA, SpringWorks

Germany’s Merck in Talks to Buy SpringWorks Therapeutics
Germany’s Merck KGaA is in advanced talks to aquire the U.S. biopharmaceutical company that specializes in rare diseases and cancer.
Merck KGaA in Talks to Buy SpringWorks Therapeutics
Merck KGaA is in advanced talks to buy US cancer and rare diseases drugmaker SpringWorks Therapeutics Inc., according to a report from Reuters, citing people familiar with the matter.
SpringWorks shares up 39% to $55.90 after Merck KGaA confirms talks
EST SpringWorks shares up 39% to $55.90 after Merck KGaA (MKGAY) confirms talksMaximize Your Portfolio with Data Driven Insights:Leverage
Merck In Talks to Buy Cancer Drugmaker Springworks
After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.
Germany's Merck in advanced talks to acquire US biotech firm SpringWorks
Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks Therapeutics. Merck, in a statement, said its negotiations to buy SpringWorks are ongoing,
EQS-Adhoc: Merck KGaA: Merck KGaA confirms discussions with Springworks Therapeutics, Inc. on potential acquisition
Merck KGaA (“Merck”) reacts to press reports and confirms advanced discussions with Springworks Therapeutics, Inc. Merck also confirms that no legally binding agreement has been entered into. There is no certainty that any transaction will materialize.
FiercePharma1h
UPDATED: Merck KGaA sets its sights on acquisition of Ogsiveo maker SpringWorks
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
SpringWorks Stock Jumps More Than 30% on News of Possible Deal
Key Takeaways Shares of SpringWorks Therapeutics soared on Monday following a report that German medical firm Merck KGaA ...
BioSpace36m
Merck KGaA Courts Cancer Biotech SpringWorks for Potential Buyout
Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...
pharmaphorum59m
Merck confirms its interest in buying SpringWorks
Merck said in a brief statement that discussions are "advanced" but noted that "critical conditions have yet to be met" ...
Springworks Therapeutics (SWTX) Gets a Buy from Barclays
Barclays analyst Peter Lawson maintained a Buy rating on Springworks Therapeutics (SWTX – Research Report) today and set a price target of ...
SpringWorks Therapeutics may be worth around $77 a share in a takeover - analyst
SpringWorks Therapeutics (SWTX) may be acquired by Merck KGaA for $77 per share, representing a potential premium of 92% ...
Why SpringWorks Therapeutics Inc. (SWTX) Soared on Monday
We recently compiled a list of the 10 Firms Begin Trading Week With Impressive Gains. In this article, we are going to take a ...